Trial Profile
A phase II trial of TPIV-200 in patients with triple negative breast cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs TPIV 200 (Primary) ; Granulocyte macrophage colony stimulating factor
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- 17 Oct 2018 According to a Marker Therapeutics Inc, the TapImmune merged with Marker Therapeutics and changed its name to Marker Therapeutics Inc.
- 05 Apr 2018 According to a TapImmune media release, this study is completely funded by a $13.3 milliongrant from the U.S. Department of Defense.
- 05 Apr 2018 According to a TapImmune media release, Mayo Clinic successfully dosed the first patient in this study.